Centre for Biochemical Pharmacology, William Harvey Research Institute, Barts and The London School of Medicine and Dentistry, Queen Mary University of London, London EC1M 6BQ, UK.
Centre for Inflammation and Therapeutic Innovation, Queen Mary University of London, London EC1M 6BQ, UK.
Cells. 2021 Apr 13;10(4):881. doi: 10.3390/cells10040881.
Rheumatoid arthritis is a chronic, systemic inflammatory disease that carries an increased risk of mortality due to cardiovascular disease. The link between inflammation and atherosclerotic disease is clear; however, recent evidence suggests that inflammation may also play a role in the development of nonischemic heart disease in rheumatoid arthritis (RA) patients. We consider here the link between inflammation and cardiovascular disease in the RA community with a focus on heart failure with preserved ejection fraction. The effect of current anti-inflammatory therapeutics, used to treat RA patients, on cardiovascular disease are discussed as well as whether targeting resolution of inflammation might offer an alternative strategy for tempering inflammation and subsequent inflammation-driven comorbidities in RA.
类风湿关节炎是一种慢性、系统性炎症性疾病，由于心血管疾病而导致死亡率增加。炎症与动脉粥样硬化疾病之间的联系是明确的；然而，最近的证据表明，炎症也可能在类风湿关节炎（RA）患者非缺血性心脏病的发展中起作用。在这里，我们考虑 RA 患者中炎症与心血管疾病之间的联系，重点关注射血分数保留的心衰。讨论了用于治疗 RA 患者的当前抗炎治疗对心血管疾病的影响，以及是否针对炎症消退可能提供一种替代策略来控制 RA 中的炎症和随后的炎症驱动的合并症。
